Comparison · NCT04382586-sae
Zanubrutinib + Supportive Care vs Placebo + Supportive Care: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Zanubrutinib + Supportive Care vs Placebo + Supportive Care: serious adverse events. Trial comparisons, record NCT04382586-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04382586-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.133 | 0.0531 | 0.297 | wilson | |
| Risk in group 2 | 0.241 | 0.122 | 0.421 | wilson | |
| Risk difference, group 1 minus group 2 | -0.108 | -0.305 | 0.0943 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.552 | 0.181 | 1.69 | log | |
| Odds ratio, group 1 over group 2 | 0.484 | 0.125 | 1.87 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Zanubrutinib + Supportive Care than on Placebo + Supportive Care | 9.26 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Zanubrutinib + Supportive Care | Zanubrutinib 320 mg orally once daily for 28 days. Supportive care treatment selected and administered as deemed appropriate by the study investigator. | 4 | 30 | EG000 |
| Group 2 | Placebo + Supportive Care | Placebo orally once daily for 28 days. Supportive care treatment selected and administered as deemed appropriate by the study investigator. | 7 | 29 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 7 months
Source ClinicalTrials.gov
Trial
- Title
- Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
- NCT number
- NCT04382586
- Phases
- PHASE2
- Conditions
- COVID-19 Pulmonary Complications, COVID-19
- Interventions
- Zanubrutinib, Supportive Care, Placebo
- Lead sponsor
- BeiGene
- Results first posted
- 2022-03-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04382586?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04382586-sae